TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03879616

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: An Enhanced Reminder
Description: This study will be a randomized trial over a 6-month period (March 8 through September 7, 2019) in 3 GI endoscopy clinics (Franklin, Rock Creek, and Lone Tree). All members currently receive a text reminder 7 days prior to their procedure, which rolls over to a telephone reminder if the text cannot be delivered or the member's phone is not text-enabled. Members will be randomized either to receive this standard IVR-T protocol (control) or to receive an enhanced reminder (intervention) protocol.~Data from the randomized trial, for both intervention and control participants, will be analyzed to develop a statistical prediction rule that identifies members at highest risk of missing their procedure.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: An Enhanced Reminder
Description: This study will be a randomized trial over a 6-month period (March 8 through September 7, 2019) in 3 GI endoscopy clinics (Franklin, Rock Creek, and Lone Tree). All members currently receive a text reminder 7 days prior to their procedure, which rolls over to a telephone reminder if the text cannot be delivered or the member's phone is not text-enabled. Members will be randomized either to receive this standard IVR-T protocol (control) or to receive an enhanced reminder (intervention) protocol.~Data from the randomized trial, for both intervention and control participants, will be analyzed to develop a statistical prediction rule that identifies members at highest risk of missing their procedure.
Study: NCT00501462

Intervention type: DRUG
Group type: OTHER
Intervention: GSK189075
Description: single 250 mg dose of drug
Study: NCT00568607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFO, VP-16, DDP, DXM
Description: DXM 40 mg d1-4; IFO 1200mg/m2 d1-4; Mesna 400mg, tid, d1-4; VP-16 75 mg/m2 d1-4; DDP 20mg/m2 d1-4; q3w. Efficacy was evaluated every two cycles. If patients hadn't diseases progression, two more cycles and radiation would be administered.
Study: NCT04134169

Intervention type: OTHER
Intervention: Not applicable(observational study)
Description: Not applicable(observational study)
Study: NCT03454945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vibramycin
Description: Antibiotic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vibramycin
Description: Antibiotic

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phototherapy
Description: UVA+Psoralen

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phototherapy
Description: UVA+Psoralen
Study: NCT00626886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Collagen Sponge
Description: collagen; Bupivacaine hydrocholoride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo collagen sponge
Description: collagen
Study: NCT04695470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib and Sintilimab
Description: fruquintinib 5mg qd for 2 weeks on and 1 week off, Q3w~Sintilimab 200mg iv, Q3w
Study: NCT01104545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3614
Study: NCT05060198

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Description: AL is the current first-line antimalarial in Kenya, per Kenya Ministry of Health.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DP)
Description: DP is the current second-line antimalarial in Kenya, per Kenya Ministry of Health.
Study: NCT03499769

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: natural orifice
Description: laparoscopic total colon surgery and patients who are removed from the natural orifice and conventional will gather
Study: NCT04016103

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MY01 - Continuous Compartmental Pressure Monitor
Description: Insertion of the MY01 device for up to 24 hours for continuous monitoring of compartment pressure
Study: NCT01104545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Study: NCT00771927

Intervention type: DRUG
Intervention: Lacosamide
Description: Vimpat was used as per site routine practices, and in-line with the marketing authorization.
Study: NCT01171014

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis HN019
Description: Bifidobacterium lactis HN019, 10 billion cfu/day, once a day for 14 days
Study: NCT02671175

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dihydroartemisinin-piperaquine placebo
Description: Children will receive standard in-hospital care for severe anaemia (blood transfusion, often combined with quinine or artesunate IV/IM). All children will then receive a 3-day course of AL (whether they initially had malaria or not), which will be started in-hospital as soon as they are able to take oral medication, and will be completed at home after discharge. At 2 weeks after enrolment surviving children will be randomized to receive either a standard 3-day courses of dihydroartemisinin-piperaquine (Eurartesim®, Sigma Tau, Italy) or an identical placebo regimen at 2, 6 and 10 weeks after enrolment.
Study: NCT02871297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Target dose is 10 mg/day, however, the dose can be down- or uptitrated to 5, 15, or 20 mg/day.
Study: NCT00541931

Intervention type: DRUG
Group type: OTHER
Intervention: Dietary Supplement: LifePak Nano
Description: Daily use
Study: NCT01559337

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Nerve transfer
Description: the dorsal branch was used as a pedicle nerve for reconstructing PDN defects
Study: NCT00038090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 100 mg capsules by mouth daily each evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg/m\^2 taken by mouth each morning on days 1-4, 9-12 and 17-20.
Study: NCT03122236

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neurorehabilitation of Complex Walking
Description: Neurorehabilitation is a behavioral therapeutic approach for enhancing the neural control of task performance by: Restoration of function, specificity of training, Sensory input to the nervous system, Intensity, Repetition and Progression of training. Neurorehabilitation of complex walking will focus on the use of walking tasks that require increased attention and executive functions. The following walking tasks will be used: over obstacles, navigating around obstacles, changing speeds, on soft surfaces (exercise mat), in dim lighting, while conversing with the therapist, up/down ramps and climbing/descending stairs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neurorehabilitation of Complex Walking
Description: Neurorehabilitation is a behavioral therapeutic approach for enhancing the neural control of task performance by: Restoration of function, specificity of training, Sensory input to the nervous system, Intensity, Repetition and Progression of training. Neurorehabilitation of complex walking will focus on the use of walking tasks that require increased attention and executive functions. The following walking tasks will be used: over obstacles, navigating around obstacles, changing speeds, on soft surfaces (exercise mat), in dim lighting, while conversing with the therapist, up/down ramps and climbing/descending stairs.
Study: NCT01229007

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biostate
Description: 1 dose of 50 IU FVIII/kg body weight of Biostate administered intravenously on Day 1 in the PK component, followed by the Efficacy component for continuation of Biostate therapy, as required for a minimum of 50 exposure days.
Study: NCT03528876

Intervention type: DRUG
Group type: OTHER
Intervention: FOLFOX and FOLFIRI
Description: a biweekly regimen comprised of two cycles of FOLFOX alternating with two cycles of FOLFIRI.
Study: NCT03085134

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test infant formula with HMOs
Description: Extensively hydrolysed (whey protein) specialty infant formulas (FSMP) with HMOs intended for management of CMPA.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control infant formula without HMOs
Description: Extensively hydrolysed (whey protein) specialty infant formulas (FSMP) intended for management of CMPA.
Study: NCT01171014

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis HN019
Description: Bifidobacterium lactis HN019, 1 billion cfu/day, once a day for 14 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, once a day for 14 days
Study: NCT02674113

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: regional anesthesia bupivacaine
Description: a single shot fascia iliaca block using bupivacaine prior to hip arthroscopy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: regional anesthesia placebo
Description: subcutaneous injection procedure using a normal saline placebo (0.9% sodium chloride in water)
Study: NCT03069742

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RealRisks
Description: RealRisks is a web-based patient decision aid with modules that present information about risk assessment and chemoprevention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BNAV
Description: Breast Cancer Risk Navigation (BNAV) tool is a web-based decision support tool with modules that present pertinent information for primary care providers regarding breast cancer risk assessment and preventative measures for their patients.
Study: NCT04389710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma
Description: One to two units (200-600 mL) of ABO compatible COVID-19 convalescent plasma
Study: NCT01632592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesamorelin
Description: The Growth Hormone Releasing Hormone analogue tesamorelin, 2mg subcutaneously daily by injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo given by injection 2mg subcutaneously daily
Study: NCT04893044

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: The video was a 3 minutes and based on inoculation theory to modify behavior towards moderating the effect of alcohol use as opposed to advising no use at all.
Study: NCT00323427

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Living Well with Hearing Loss Workshop
Description: Interactive group session modeled on Patient-Centered medicine and Adult Learning principles; the participants are partners with the Group Facilitator who is a hearing rehabilitation professional
Study: NCT03122236

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation (Sham tDCS)
Description: tDCS will be used to induce positive neuromodulation of frontal/executive circuits to make them more amenable to the activity-dependent neuroplasticity that is known to occur with behavioral neurorehabilitation. Specifically, tDCS may facilitate the efficacy of our walking neurorehabilitation intervention by strengthening the synaptic connections within the recruited circuits.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation (Sham tDCS)
Description: tDCS will be used to induce positive neuromodulation of frontal/executive circuits to make them more amenable to the activity-dependent neuroplasticity that is known to occur with behavioral neurorehabilitation. Specifically, tDCS may facilitate the efficacy of our walking neurorehabilitation intervention by strengthening the synaptic connections within the recruited circuits.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Transcranial Direct Current Stimulation (Active tDCS)
Description: tDCS will be used to induce positive neuromodulation of frontal/executive circuits to make them more amenable to the activity-dependent neuroplasticity that is known to occur with behavioral neurorehabilitation. Specifically, tDCS may facilitate the efficacy of our walking neurorehabilitation intervention by strengthening the synaptic connections within the recruited circuits.
Study: NCT00942487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebilet
Description: Trade-mark: Nebilet® (Berlin-Chemie Menarini) INN: nebivolol Dosage and route of administration: 5 mg tablets, o.d. for oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corvitol
Description: Trade-mark: Corvitol (Berlin-Chemie Menarini) INN: metoprolol Dosage and route of administration: 50 mg tablets, b.d. (100 mg/day) for oral administration
Study: NCT01311622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin
Description: 2 single 25 mg doses of Warfarin (5 x 5 mg tablets) administered 14 days apart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin
Description: 2 single 25 mg doses of Warfarin (5 x 5 mg tablets) administered 14 days apart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fostamatinib
Description: 2 x 50 mg Fostamatinib tablets (100 mg) twice daily for 13 days
Study: NCT04264013

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: Participants will exercise in a supervised facility twice weekly and consume their habitual diet.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise plus diet (egg)
Description: Participants will exercise in a supervised facility twice weekly and consume an addiitonal 4 eggs per day.
Study: NCT02369484

Intervention type: DRUG
Group type: OTHER
Intervention: Afatinib
Description: 40mg p.o./ day until documented progression or unacceptable toxicity
Study: NCT00538759

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External beam radiation therapy
Description: Experimental beam radiation therapy to the aortic valve after successful balloon aortic valvuloplasty

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Control
Study: NCT02809794

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fisher & Paykel Healthcare CPAP Device
Description: Fisher \& Paykel Healthcare CPAP Device
Study: NCT04977700

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: Test the developed algorithm that delivers location-based, tailored sun safety advice to Strava users through Strava comments for acceptability, ways of interacting with it, and barriers/willingness to allowing access.
Study: NCT03610594

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kalaripayattu
Description: Combination of Exercise, breathing, meditation, combat practices
Study: NCT00323427

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hearing aid services
Description: Standard VA audiological hearing aid dispensing services
Study: NCT05530161

Intervention type: OTHER
Intervention: hypocalcemia
Description: hypocalcemia or normocalcemia
Study: NCT02675244

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TV Annuloplasty
Description: TV Annuloplasty will be performed using standard surgical techniques

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MVS
Description: MVS will be performed using standard surgical techniques

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MVS
Description: MVS will be performed using standard surgical techniques
Study: NCT03819166

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: with deep touch pressure application
Description: The deep touch pressure is applied by the weight loading devices, including but not limited to, weight blanket and weight vest.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: without deep touch pressure application
Description: The deep touch pressure will not be applied.
Study: NCT01460888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 25mg tablets, oral. Commenced 3 days prior to radiotherapy and continuing until the last day of radiotherapy (36 days in total).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 25mg tablets, oral. Commenced 3 days prior to radiotherapy and continuing until the last day of radiotherapy (36 days in total).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 25mg tablets, oral. Commenced 3 days prior to radiotherapy and continuing until the last day of radiotherapy (36 days in total).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 25mg tablets, oral. Commenced 3 days prior to radiotherapy and continuing until the last day of radiotherapy (36 days in total).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radical external beam radiotherapy, 50Gy in 25 fractions
Description: Radiotherapy to the oesophageal carcinoma. For patients receiving olaparib this is delivered as 50Gy in 25 daily fractions for 5 weeks (Monday-Friday only). For patients in the comparator arm (RT only) other total doses/ fractionation are permitted, according to local policy/ best standard care.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radical external beam radiotherapy, 50Gy in 25 fractions
Description: Radiotherapy to the oesophageal carcinoma. For patients receiving olaparib this is delivered as 50Gy in 25 daily fractions for 5 weeks (Monday-Friday only). For patients in the comparator arm (RT only) other total doses/ fractionation are permitted, according to local policy/ best standard care.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radical external beam radiotherapy, 50Gy in 25 fractions
Description: Radiotherapy to the oesophageal carcinoma. For patients receiving olaparib this is delivered as 50Gy in 25 daily fractions for 5 weeks (Monday-Friday only). For patients in the comparator arm (RT only) other total doses/ fractionation are permitted, according to local policy/ best standard care.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radical external beam radiotherapy, 50Gy in 25 fractions
Description: Radiotherapy to the oesophageal carcinoma. For patients receiving olaparib this is delivered as 50Gy in 25 daily fractions for 5 weeks (Monday-Friday only). For patients in the comparator arm (RT only) other total doses/ fractionation are permitted, according to local policy/ best standard care.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radical external beam radiotherapy, 50Gy in 25 fractions
Description: Radiotherapy to the oesophageal carcinoma. For patients receiving olaparib this is delivered as 50Gy in 25 daily fractions for 5 weeks (Monday-Friday only). For patients in the comparator arm (RT only) other total doses/ fractionation are permitted, according to local policy/ best standard care.
Study: NCT02515825

Intervention type: DEVICE
Intervention: CADence

Intervention type: DEVICE
Intervention: CADence
Study: NCT00680017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-335 plus rosuvastatin
Description: ABT-335 45 mg plus rosuvastatin 5 mg for 8 weeks, then ABT-335 45 mg plus rosuvastatin 10 mg for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin 5 mg for 8 weeks then rosuvastatin 10 mg for 8 weeks
Study: NCT01509950

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Staples
Description: Staples for closure of cesarean section skin incision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prolene non-absorbable sutures
Description: Prolene non-absorbable sutures for closure of cesarean skin incision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Absorbable Sutures
Description: Absorbable sutures for closure of cesarean skin incision
Study: NCT03763682

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genio(TM) bilateral hypoglossal nerve stimulation system
Description: Subjects will be consented, enrolled and eligibility criteria checked. If the subject is eligible, subject will proceed with the Genio(TM) implant implantation. Six (6) weeks after implantation, the implant will be activated and the subject will be assessed at 1 month plus 1 week, 2, 3, 4, 5 and 6 month(s) after implantation
Study: NCT02542683

Intervention type: OTHER
Intervention: structured physical activity program
Description: a structured modest physical activity program
Study: NCT00441298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir gel
Description: Participants will be provided with a supply of single-use, pre-filled applicators according to their randomisation. While in the study, participants will be asked to apply a first dose of the assigned study product, 1% tenofovir gel, within 12 hours prior to coitus and insert a second dose as soon as possible within 12 hours after coitus. They will be advised to use only two doses of gel in a 24-hour period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Universal HEC placebo)
Description: Participants will be provided with a supply of single-use, pre-filled applicators according to their randomisation. While in the study, participants will be asked to apply a first dose of the assigned study product, placebo gel, within 12 hours prior to coitus and insert a second dose as soon as possible within 12 hours after coitus. They will be advised to use only two doses of gel in a 24-hour period.
Study: NCT00599469

Intervention type: RADIATION
Group type: OTHER
Intervention: Far Infrared Radiation (5μm to 20μm wavelength)
Description: Far Infrared radiation for 30 to 40 minutes per treatment session.
Study: NCT00323427

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hearing aid services
Description: Standard VA audiological hearing aid dispensing services
Study: NCT03313804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitor
Description: Standard of care immune checkpoint inhibitor

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Stereotactic Body Radiation Therapy OR Fractionated radiation therapy
Study: NCT01225276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NewGam 10%
Description: Loading dose at baseline (Week 0) will be 2.0 g/kg NewGam . The maintenance doses to be infused 7 times will be 2.0 g/kg every 21 (+/-4) days.
Study: NCT00269113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: 375mg/m2 iv monthly for 8 cycles